Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | PARP1 | P09874 | 1/20 | 0.30 |
| ▸ | CES1 | P23141 | 1/20 | 0.30 |
| ▸ | MAOA | P21397 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19194983 | 0.77 | PARP1 (0.36) | MEN1KMT2ACYP1A2PARP1 | |
| SCHEMBL4032757 | 0.73 | TSHR (0.32) | TSHRPARP1MAOA | |
| SCHEMBL4872275 | 0.68 | MEN1 (0.43) | MEN1KMT2ACYP1A2 | |
| SCHEMBL255964 | 0.66 | KMT2A (0.64) | MEN1KMT2ACYP1A2TSHRCES1 | |
| SCHEMBL29657671 | 0.66 | KMT2A (0.64) | MEN1KMT2ACYP1A2TSHRCES1 | |
| SCHEMBL1653382 | 0.63 | TRPA1 (0.35) | MEN1KMT2A | |
| SCHEMBL25757622 | 0.62 | MEN1 (0.41) | MEN1KMT2ACYP1A2TSHRCES1 | |
| SCHEMBL255961 | 0.57 | MEN1 (0.46) | MEN1KMT2ACYP1A2TSHRCES1 | |
| SCHEMBL2376272 | 0.57 | GPR3 (0.42) | MEN1KMT2A | |
| SCHEMBL31028936 | 0.56 | AHR (0.39) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 562 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11236097-B2 | 11,13-modified saxitoxins for the treatment of pain | SITEONE THERAPEUTICS, INC. (US) | 2022-02-01 | — | — | US | claimed |
| US-20220009938-A1 | 11,13-MODIFIED SAXITOXINS FOR THE TREATMENT OF PAIN | SITEONE THERAPEUTICS, INC. | 2022-01-13 | — | — | US | claimed |
| EP-3860714-A1 | 11,13-MODIFIED SAXITOXINS FOR THE TREATMENT OF PAIN | Siteone Therapeutics, Inc. (US) | 2021-08-11 | — | — | EP | claimed |
| WO-2020072835-A1 | 11,13-MODIFIED SAXITOXINS FOR THE TREATMENT OF PAIN | SITEONE THERAPEUTICS, INC. (US) | 2020-04-09 | — | — | WO | claimed |
| US-20200102318-A1 | 11,13-MODIFIED SAXITOXINS FOR THE TREATMENT OF PAIN | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2020-04-02 | — | — | US | claimed |
| CN-110831945-A | 11, 13-modified saxitoxins for the treatment of pain | 赛特温治疗公司 | 2020-02-21 | — | — | CN | claimed |
| EP-3601291-A1 | 11,13-MODIFIED SAXITOXINS FOR THE TREATMENT OF PAIN | Siteone Therapeutics, Inc. (US) | 2020-02-05 | — | — | EP | claimed |
| WO-2018183781-A1 | 11,13-MODIFIED SAXITOXINS FOR THE TREATMENT OF PAIN | SITEONE THERAPEUTICS, INC. (US) | 2018-10-04 | — | — | WO | claimed |
| US-8466295-B2 | Thiophene derivatives as factor XIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-06-18 | — | — | US | claimed |
| US-8404692-B2 | Pyrimidin-4-yl-3, 4-dihydro-2H-pyrrolo [1,2A] pyrazin-1-one compounds | CYCLACEL LIMITED (GB) | 2013-03-26 | — | — | US | claimed |
| CN-101326188-A | Pyrimidin-4-yl-3, 4-dihydro-2H-pyrrolo [1,2A ] pyrazin-1-one compounds | CYCLACEL LTD (GB) | 2008-12-17 | — | — | CN | claimed |
| EP-1981854-A1 | ARYLPROPIONAMIDE, ARYLACRYLAMIDE, ARYLPROPYNAMIDE, OR ARYLMETHYLUREA ANALOGS AS FACTOR XIA INHIBITORS | Brystol-Myers Squibb Company (US) | 2008-10-22 | — | — | EP | claimed |
| EP-1966141-A1 | SIX-MEMBERED HETEROCYCLES USEFUL AS SERINE PROTEASE INHIBITORS | Brystol-Myers Squibb Company (US) | 2008-09-10 | — | — | EP | claimed |
| EP-1940846-A2 | PYRIMIDIN-4-YL-3,4-DIHYDRO-2H-PYRROLO[1,2A]PYRAZIN-1-ONE COMPOUNDS | Cyclacel Limited (GB) | 2008-07-09 | — | — | EP | claimed |
| US-20080161373-A1 | ARYLPROPIONAMIDE, ARYLACRYLAMIDE, ARYLPROPYNAMIDE, OR ARYLMETHYLUREA ANALOGS AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB CO. | 2008-07-03 | — | — | US | claimed |
| US-20080119535-A1 | AMINOMETHYL-4-IMIDAZOLES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-05-22 | — | — | US | claimed |
| WO-2007070818-A1 | SIX-MEMBERED HETEROCYCLES USEFUL AS SERINE PROTEASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-06-21 | — | — | WO | claimed |
| WO-2007070816-A2 | THIOPHENE DERIVATIVES AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-06-21 | — | — | WO | claimed |
| WO-2007070826-A1 | ARYLPROPIONAMIDE, ARYLACRYLAMIDE, ARYLPROPYNAMIDE, OR ARYLMETHYLUREA ANALOGS AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-06-21 | — | — | WO | claimed |
| WO-2007042784-A2 | PYRIMIDIN-4-YL-3, 4-DIHYDR0-2H- PYRROLO [1, 2A] PYRAZIN-1-ONE COMPOUNDS | CYCLACEL LIMITED (GB) | 2007-04-19 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11236097-B2 | 11,13-modified saxitoxins for the treatment of pain | SCN11A, SCN10A, CACNA1A | MEN1 3440/4885KMT2A 2484/4885CYP1A2 2635/4885 |
| US-20080161373-A1 | ARYLPROPIONAMIDE, ARYLACRYLAMIDE, ARYLPROPYNAMIDE, OR ARYLMETHYLUREA ANALOGS AS FACTOR XIA INHIBITORS | TFPI, F11, F12 | MEN1 1706/4885KMT2A 235/4885CYP1A2 510/4885 |
| US-20080119535-A1 | AMINOMETHYL-4-IMIDAZOLES | INMT, HTR4, MC4R | MEN1 941/4885KMT2A 282/4885CYP1A2 212/4885 |
| US-20200102318-A1 | 11,13-MODIFIED SAXITOXINS FOR THE TREATMENT OF PAIN | SCN11A, SCN10A, CACNA1A | MEN1 3440/4885KMT2A 2484/4885CYP1A2 2635/4885 |
| US-20220009938-A1 | 11,13-MODIFIED SAXITOXINS FOR THE TREATMENT OF PAIN | SCN11A, SCN10A, SCN3A | MEN1 2889/4885KMT2A 3816/4885CYP1A2 3012/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.